Skip to main content
. 2021 Dec 14;7(3):436–443. doi: 10.1016/j.ekir.2021.12.013

Figure 3.

Figure 3

UACR over time in participants with and without MRA use at baseline. (a) With MRA use at baseline. (b) Without MRA use at baseline. MRA, mineralocorticoid receptor antagonists; LS, least-squared; UACR, urine albumin-to creatinine ratio.